Latest:
First Closed Scientific Expert Meeting of the Editorial Board
About Lp(a) Forum
The Lp(a) Forum is a new, independent, non-profit, expert-led, global initiative providing clinicians and researchers worldwide with open access, peer-reviewed resources devoted to the exciting and rapidly developing area of Lp(a) science and therapeutics.
The Forum brings together internationally-recognised experts from the scientific and clinical communities who are committed to developing awareness, knowledge and understanding of the importance of Lp(a) as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, even when LDL-cholesterol levels are low… Read more
Free Membership
Lp(a) Forum Co-Chair, Professor John Chapman, invites you to join Lp(a) Forum for open access to multimedia educational resources about Lp(a) science, management and research.
Why do we need this Forum?
In recent years, unequivocal evidence has been published supporting Lp(a) as a target for lipid lowering therapies to reduce cardiovascular risk in individuals with significantly elevated Lp(a) levels. Innovative Lp(a) targeted therapies are in development and there is now an urgent need for reliable, accessible scientific and clinical information about Lp(a) for the clinical and scientific community that is appropriate for all levels of expertise and interest.
Lp(a) Forum Co-Chair, Professor John Chapman, turns the spotlight on the accumulating observational, genetic and mechanistic evidence supporting Lp(a) as an independent, causal risk factor for cardiovascular disease, and discusses the promise of novel Lp(a)-lowering agents in development.
Lp(a) Forum Co-Chair, Professor Henry Ginsberg, explains why the time is right to focus on Lp(a) as an important risk factor for cardiovascular disease and to ensure that current knowledge and news of future advances are accessible to clinicians and researchers worldwide.
Expert Views
The importance of Lp(a) testing
Professor Keith Ferdinand, Tulane University School of Medicine, New Orleans, USA, highlights the importance of testing Lp(a) levels.
Lp(a) and coronary plaque progression
Professor Marc Dweck, University of Edinburgh, UK, reports recent imaging research that links Lp(a) to progression of the most unstable coronary plaques.
The genetics of Lp(a)
Professor Florian Kronenberg, Medical University of Innsbruck, Austria, shows how the genetics of Lp(a) is informing links with cardiovascular outcomes.
Diversity in Lp(a) across ancestry and gender
Professor Pia Kamstrup, Copenhagen University Hospital, Denmark, discusses the evidence and its implications for cardiovascular risk in different populations.
Lipoprotein(a) as a CVD risk factor
Dr Anne Langsted, Rigshospitalet, Copenhagen, Denmark, considers the pivotal studies that are shaping current clinical practice and future expectations.
Slides
Lp(a): A new causal risk factor for ASCVD and aortic valve stenosis
Download this topical introductory slide deck to Lp(a), developed by Lp(a) Forum Co-Chair, Professor John Chapman, which summarises key evidence supporting the role of Lp(a) as a causal risk factor in cardiovascular disease
Trials
Multiple Lp(a) targeted therapeutics are undergoing extensive clinical trials to investigate their safety, efficacy and tolerability, and potential benefits for cardiovascular outcomes.
Lp(a): What do the guidelines say?
Multiple expert guidelines recognise Lp(a) as a risk factor for cardiovascular disease and advise on Lp(a) measurement and treatment as part of broader risk management…
Back to Basics
Back to Basics summarises current thinking on key aspects of Lp(a) science and management
What is Lp(a)
Lp(a) is a plasma lipoprotein that consists of an LDL-like particle in which apolipoprotein B100 is covalently linked to the plasminogen-like protein…
Read more
Lp(a) measurement
Lp(a) level is measured as Lp(a) particle number (nmol/L) or Lp(a) mass concentration (mg/dL), and levels ≥100/125 nmol/L (≥50 mg/dL) are …
Read more
Why test Lp(a)?
Professor Keith Ferdinand, Tulane University School of Medicine, New Orleans, USA, discusses the advantages of Lp(a) testing for patients and their families…
Read more
Lp(a) and CVD
Elevated Lp(a) is associated with increased risk of coronary heart disease, ischaemic stroke, peripheral artery disease, heart failure, aortic stenosis and mortality …
Read more
Lp(a) therapies
No Lp(a) targeted therapies have been approved, but experts agree that intensive management of other risk factors is important in individuals with elevated …
Read more
Journal Updates
UK lipid guidance recommends Lp(a) measurement in enhanced lipid profiling New UK lipid guidance recommends Lp(a) measurement to be included in enhanced lipid profiling …
Apo(a) isoform size affects Lp(a) response to lipid lowering therapy People with larger apo(a) size have the greatest reduction in Lp(a) level in response to …
Elevated Lp(a) linked to MACE independently of hs-CRP level
Elevated Lp(a) is associated with an increased risk of major adverse cardiovascular events …
Zerlasiran and muvalaplin studies published Results of Phase 2 studies of zerlasiran and muvalaplin in patients with elevated Lp(a) …
Lowering LDL-C does not fully offset ASCVD risk of elevated Lp(a) Lp(a) and LDL-C have independent and additive adverse effects on risk of atherosclerotic cardiovascular disease (ASCVD), and lowering LDL-C …
Latest Congress Highlights
Our highlights from the American Heart Association Scientific Sessions 2024 (November 16-18, Chicago, USA and online), include promising new clinical data on novel Lp(a) lowering agents. We also report studies on the impact of Lp(a) testing in clinical practice and its potential for identifying vulnerable individuals with coronary artery disease, and there is news of research into a possible role for lipid lowering treatment in patients with aortic valve calcification.
Upcoming Congress
ACC 2025
29-31 March, Chicago, USA.
Other Congress News
Among the highlights of the ESC 2024 Congress (30 August-2 September, London, UK, and online), expert lipid specialists discussed latest progress in understanding of the role of Lp(a) in aortic stenosis, the benefits of Lp(a) testing on lipid control, the potential need for repeat Lp(a) measurement, implications of elevated Lp(a) for coronary calcium score, and the relevance of Lp(a) genotype.
Video Library
International experts discuss hot topics on all aspects of the epidemiology, genetics and pathophysiology of Lp(a).
